Related Experiment Video
Updated: Jun 16, 2026
09:39
Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
Published on: July 29, 2016
Prostaglandin D2 inhibits C2C12 myogenesis
Pedro Veliça1, Farhat L Khanim, Chris M Bunce
1School of Biosciences, College of Life and Environmental Sciences, University of Birmingham, Edgbaston, Birmingham, UK. velica@gmail.com
Molecular and Cellular Endocrinology
|January 30, 2010
Summary
Prostaglandin D2 (PGD2) from inflammation significantly hinders muscle stem cell (myoblast) regeneration. This novel PGD2 signaling pathway impacts muscle repair and suggests caution with anti-inflammatory drugs during recovery.
Area of Science:
- Biochemistry
- Cell Biology
- Muscle Physiology
Background:
- Muscle injury triggers an inflammatory response involving leukocytes releasing prostaglandin D2 (PGD2).
- Myoblasts, crucial for muscle repair, are exposed to high PGD2 levels during this inflammatory phase.
Purpose of the Study:
- To investigate the inhibitory effects of PGD2 on myogenesis (muscle cell formation).
- To elucidate the signaling mechanism by which PGD2 affects myoblasts during muscle repair.
Main Methods:
- Assessing C2C12 myogenesis via cell fusion, creatine kinase activity, and expression of key muscle proteins (MyoD, myogenin, alpha-actin).
- Evaluating PGD2's effects at micromolar concentrations and testing for involvement of known PGD2 receptors (DP1, DP2).
- Comparing PGD2's mechanism to its derivative 15-deoxy-Delta(12,14)-PGJ2 (15d-PGJ2) by measuring mitochondrial superoxide generation.
Main Results:
- PGD2 significantly inhibited C2C12 myogenesis, affecting cell fusion and muscle-specific gene/protein expression.
- Inhibition occurred at micromolar PGD2 concentrations and was independent of DP1 and DP2 receptors.
- PGD2 did not induce toxic mitochondrial superoxide, differentiating its mechanism from 15d-PGJ2.
Conclusions:
- A novel signaling pathway for PGD2 in muscle repair has been identified, mediated by high inflammatory PGD2 concentrations.
- This highlights a complex interaction between myoblasts and inflammatory cells.
- Findings suggest potential implications for using non-steroidal anti-inflammatory drugs in treating muscle injuries.
Related Concept Videos
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:09GPCRs Regulate Adenylyl Cylase Activity
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Two...
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...